Literature DB >> 11855931

Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro.

A Helip-Wooley1, M A Park, R M Lemons, J G Thoene.   

Abstract

Mutations in CTNS result in one of three forms of cystinosis: benign, intermediate, or nephropathic. Homozygosity for a nonsense mutation in CTNS (753G -->A), encoding a premature termination codon (PTC) at amino acid 138 (W138X), results in nephropathic cystinosis. Gentamicin is known to induce PTC readthrough and hence full-length protein production. We demonstrate that addition of gentamicin (300 microg/ml) to cystinotic fibroblasts leads to depletion of intracellular cystine in cell lines with a premature termination codon, but not in those with a large deletion or a deletion leading to a frameshift mutation. Plasmids were constructed with GFP as a C-terminal or N-terminal fusion to CTNS. The normal CTNS protein fused with either N- or C-terminal GFP colocalized with Lysotracker red, a fluorescent stain which selectively accumulates in lysosomes. PTC-GFP, a construct with GFP fused to the C-terminus of CTNS containing a PTC, allowed GFP to serve as a reporter of PTC readthrough. No significant fluorescence was observed in PTC-GFP-transfected cells in the absence of gentamicin but was seen and localized to lysosomes in its presence. A patient with a splice site mutation (IVS11 + 2T -->C) that eliminates the GYDQL lysosomal targeting sequence of cystinosin on one allele, and a PTC mutation (753G -->A) on the other, displays the intermediate phenotype. Transfection of the splice site mutant allele into CTNS null fibroblasts produced cystine depletion. Plasmids with GFP fused to the N-terminus of CTNS containing the splice site mutation (GFP-SS) were constructed. While the normal CTNS-GFP fusion protein was found to colocalize with Lysotracker red almost exclusively, the GFP-SS fusion product was found in the plasma membrane and cytoplasm, as well as lysosomes. A second lysosomal targeting motif in CTNS is present in this sequence, just proximal to the mutation, accounting for the partial lysosomal localization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855931     DOI: 10.1006/mgme.2001.3272

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  14 in total

1.  A breakthrough in readthrough? Could geneticin lead the way to effective treatment for cystinosis nonsense mutations?

Authors:  Julian Midgley
Journal:  Pediatr Nephrol       Date:  2019-01-08       Impact factor: 3.714

2.  When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.

Authors:  Moran Shalev; Timor Baasov
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

3.  The aminoglycoside geneticin permits translational readthrough of the CTNS W138X nonsense mutation in fibroblasts from patients with nephropathic cystinosis.

Authors:  Emma J Brasell; LeeLee Chu; Reyhan El Kares; Jung Hwa Seo; Robin Loesch; Diana M Iglesias; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2018-11-09       Impact factor: 3.714

4.  Readthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease.

Authors:  B Pérez; P Rodríguez-Pombo; M Ugarte; L R Desviat
Journal:  Mol Syndromol       Date:  2012-10-02

5.  Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons.

Authors:  Chih-Hung Lai; Helen H Chun; Shareef A Nahas; Midori Mitui; Kristin M Gamo; Liutao Du; Richard A Gatti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-21       Impact factor: 11.205

Review 6.  New aspects of the pathogenesis of cystinosis.

Authors:  Vasiliki Kalatzis; Corinne Antignac
Journal:  Pediatr Nephrol       Date:  2003-02-27       Impact factor: 3.714

Review 7.  Making sense of nonsense GABA(A) receptor mutations associated with genetic epilepsies.

Authors:  Jing-Qiong Kang; Robert L Macdonald
Journal:  Trends Mol Med       Date:  2009-08-31       Impact factor: 11.951

8.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; Timea Kovaçs; Eric Sorscher; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

9.  G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis.

Authors:  Rustam Azimov; Natalia Abuladze; Pakan Sassani; Debra Newman; Liyo Kao; Weixin Liu; Nicholas Orozco; Piotr Ruchala; Alexander Pushkin; Ira Kurtz
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-09

10.  Nonaminoglycoside compounds induce readthrough of nonsense mutations.

Authors:  Liutao Du; Robert Damoiseaux; Shareef Nahas; Kun Gao; Hailiang Hu; Julianne M Pollard; Jimena Goldstine; Michael E Jung; Susanne M Henning; Carmen Bertoni; Richard A Gatti
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.